![Discovery of Balovaptan, a Vasopressin 1a Receptor Antagonist for the Treatment of Autism Spectrum Disorder | Journal of Medicinal Chemistry Discovery of Balovaptan, a Vasopressin 1a Receptor Antagonist for the Treatment of Autism Spectrum Disorder | Journal of Medicinal Chemistry](https://pubs.acs.org/cms/10.1021/acs.jmedchem.9b01478/asset/images/large/jm9b01478_0005.jpeg)
Discovery of Balovaptan, a Vasopressin 1a Receptor Antagonist for the Treatment of Autism Spectrum Disorder | Journal of Medicinal Chemistry
Discovery of Balovaptan, a Vasopressin 1a Receptor Antagonist for the Treatment of Autism Spectrum Disorder | Journal of Medicinal Chemistry
![Discovery of Balovaptan, a Vasopressin 1a Receptor Antagonist for the Treatment of Autism Spectrum Disorder | Journal of Medicinal Chemistry Discovery of Balovaptan, a Vasopressin 1a Receptor Antagonist for the Treatment of Autism Spectrum Disorder | Journal of Medicinal Chemistry](https://pubs.acs.org/cms/10.1021/acs.jmedchem.9b01478/asset/images/medium/jm9b01478_0001.gif)
Discovery of Balovaptan, a Vasopressin 1a Receptor Antagonist for the Treatment of Autism Spectrum Disorder | Journal of Medicinal Chemistry
![Efficacy and safety of balovaptan for socialisation and communication difficulties in autistic adults in North America and Europe: a phase 3, randomised, placebo-controlled trial - The Lancet Psychiatry Efficacy and safety of balovaptan for socialisation and communication difficulties in autistic adults in North America and Europe: a phase 3, randomised, placebo-controlled trial - The Lancet Psychiatry](https://www.thelancet.com/cms/attachment/ad808937-26eb-4d92-8a40-ef081573173d/gr1_lrg.gif)
Efficacy and safety of balovaptan for socialisation and communication difficulties in autistic adults in North America and Europe: a phase 3, randomised, placebo-controlled trial - The Lancet Psychiatry
![A perspective on molecular signalling dysfunction, its clinical relevance and therapeutics in autism spectrum disorder | SpringerLink A perspective on molecular signalling dysfunction, its clinical relevance and therapeutics in autism spectrum disorder | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs00221-022-06448-x/MediaObjects/221_2022_6448_Fig4_HTML.png)
A perspective on molecular signalling dysfunction, its clinical relevance and therapeutics in autism spectrum disorder | SpringerLink
![Discovery of Balovaptan, a Vasopressin 1a Receptor Antagonist for the Treatment of Autism Spectrum Disorder | Journal of Medicinal Chemistry Discovery of Balovaptan, a Vasopressin 1a Receptor Antagonist for the Treatment of Autism Spectrum Disorder | Journal of Medicinal Chemistry](https://pubs.acs.org/cms/10.1021/acs.jmedchem.9b01478/asset/images/large/jm9b01478_0002.jpeg)
Discovery of Balovaptan, a Vasopressin 1a Receptor Antagonist for the Treatment of Autism Spectrum Disorder | Journal of Medicinal Chemistry
![A randomized placebo-controlled pilot trial shows that intranasal vasopressin improves social deficits in children with autism | Science Translational Medicine A randomized placebo-controlled pilot trial shows that intranasal vasopressin improves social deficits in children with autism | Science Translational Medicine](https://www.science.org/cms/10.1126/scitranslmed.aau7356/asset/67f9038d-8c8b-47ae-9689-902fd99866b8/assets/graphic/aau7356-f1.jpeg)
A randomized placebo-controlled pilot trial shows that intranasal vasopressin improves social deficits in children with autism | Science Translational Medicine
![Frontiers | Untangle the Multi-Facet Functions of Auts2 as an Entry Point to Understand Neurodevelopmental Disorders Frontiers | Untangle the Multi-Facet Functions of Auts2 as an Entry Point to Understand Neurodevelopmental Disorders](https://www.frontiersin.org/files/Articles/580433/fpsyt-12-580433-HTML/image_m/fpsyt-12-580433-g001.jpg)
Frontiers | Untangle the Multi-Facet Functions of Auts2 as an Entry Point to Understand Neurodevelopmental Disorders
![The study design is as explained in Figures 4 and 5. Sal and VPA rats... | Download Scientific Diagram The study design is as explained in Figures 4 and 5. Sal and VPA rats... | Download Scientific Diagram](https://www.researchgate.net/publication/225030216/figure/fig10/AS:213848930951169@1427996966110/The-study-design-is-as-explained-in-Figures-4-and-5-Sal-and-VPA-rats-were-subdivided.png)
The study design is as explained in Figures 4 and 5. Sal and VPA rats... | Download Scientific Diagram
Bioavailability and pharmacokinetic profile of balovaptan, a selective, brain-penetrant vasopressin 1a receptor antagonist, in h
Bioavailability and pharmacokinetic profile of balovaptan, a selective, brain-penetrant vasopressin 1a receptor antagonist, in h
![Discovery of Balovaptan, a Vasopressin 1a Receptor Antagonist for the Treatment of Autism Spectrum Disorder | Journal of Medicinal Chemistry Discovery of Balovaptan, a Vasopressin 1a Receptor Antagonist for the Treatment of Autism Spectrum Disorder | Journal of Medicinal Chemistry](https://pubs.acs.org/cms/10.1021/acs.jmedchem.9b01478/asset/images/medium/jm9b01478_0008.gif)
Discovery of Balovaptan, a Vasopressin 1a Receptor Antagonist for the Treatment of Autism Spectrum Disorder | Journal of Medicinal Chemistry
![Discovery of Balovaptan, a Vasopressin 1a Receptor Antagonist for the Treatment of Autism Spectrum Disorder | Journal of Medicinal Chemistry Discovery of Balovaptan, a Vasopressin 1a Receptor Antagonist for the Treatment of Autism Spectrum Disorder | Journal of Medicinal Chemistry](https://pubs.acs.org/cms/10.1021/acs.jmedchem.9b01478/asset/images/medium/jm9b01478_0017.gif)
Discovery of Balovaptan, a Vasopressin 1a Receptor Antagonist for the Treatment of Autism Spectrum Disorder | Journal of Medicinal Chemistry
![Signalling pathways in autism spectrum disorder: mechanisms and therapeutic implications | Signal Transduction and Targeted Therapy Signalling pathways in autism spectrum disorder: mechanisms and therapeutic implications | Signal Transduction and Targeted Therapy](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41392-022-01081-0/MediaObjects/41392_2022_1081_Fig4_HTML.png)